<br>依曲莫德：一种用于治疗溃疡性结肠炎的鞘氨醇-1-磷酸受体调节剂,Annals of Pharmacotherapy

当前位置： X-MOL 学术 › Ann. Pharmacother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

依曲莫德：一种用于治疗溃疡性结肠炎的鞘氨醇-1-磷酸受体调节剂
Annals of Pharmacotherapy ( IF 2.3 ) Pub Date : 2024-01-23 , DOI: 10.1177/10600280231225770
David Choi ₁ , Michelle Becker ₂ , Marina Ivanov ₃ , Shubha Bhat ₄

Affiliation

目的：回顾依曲莫德治疗溃疡性结肠炎（UC）的药理学和临床特征。数据来源：从建库到 2023 年 11 月，使用关键词 etrasimod、ulcerative colitis和 sphingosine-1-phosphate receptor modulator 进行了 PubMed 检索。信息也来自已发表的摘要和包装说明书。研究选择和资料提取：回顾了 2 期和 3 期研究以及关于 etrasimod 药理学和临床特征的相关文献。数据综合：根据 ELEVATE，2 项 3 期研究，与安慰剂相比，etrasimod 在诱导和维持阶段实现临床缓解的中度至重度活动性 UC 患者比例更高。此外，与安慰剂相比，依曲莫德组达到临床反应、内窥镜改善-组织学缓解、无皮质类固醇缓解和内窥镜改善等次要终点的患者比例更高。常见的不良事件包括贫血和头痛。与现有药物相比，与患者护理和临床实践的相关性：Etrasimod 现在是第二个被批准用于 UC 的口服鞘氨醇-1-磷酸调节剂，为患者提供了额外的治疗选择。这种治疗的有效率与其他 UC 药物选择一致。与其他鞘氨醇-1-磷酸受体调节剂类似，在基线和治疗期间需要进行各种评估，以确保安全和适当使用。结论： Etrasimod 是 UC 治疗武器库中的另一种可能性，为患者提供了更多的口服用药选择。在治疗开始之前，建议进行与安全性、药物相互作用和药物基因组学因素相关的几项评估。

"点击查看英文标题和摘要"

Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis

Objective:To review the pharmacologic and clinical profile of etrasimod in the treatment of ulcerative colitis (UC).Data sources:A PubMed search was conducted from inception to November 2023 using the keywords etrasimod, ulcerative colitis, and sphingosine-1-phosphate receptor modulator. Information was also obtained from published abstracts and package insert.Study selection and data extraction:Phase 2 and 3 studies plus relevant literature on etrasimod pharmacologic and clinical profile were reviewed.Data synthesis:Per ELEVATE, 2 phase 3 studies, a higher proportion of patients with moderately to severely active UC achieved clinical remission in the induction and maintenance phase with etrasimod compared with placebo. In addition, a higher proportion of patients achieved secondary endpoints of clinical response, endoscopic improvement-histologic remission, corticosteroid-free remission, and endoscopic improvement with etrasimod vs placebo. Common adverse events include anemia and headache.Relevance to patient care and clinical practice in comparison with existing drugs:Etrasimod is now the second orally administered sphingosine-1-phosphate modulator approved for UC, providing patients with additional treatment options. Efficacy rates of this treatment are in line with other UC medication options. Similar to other sphingosine-1-phosphate receptor modulators, various assessments are required at baseline and during treatment to ensure safe and appropriate use.Conclusion:Etrasimod is another possibility in the armamentarium of UC treatment, providing patients with more oral medication options. Prior to treatment initiation, several assessments relating to safety, drug interactions, and pharmacogenomics factors are advised.

更新日期：2024-01-23

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南